[A24-108] Epcoritamab (DLBCL, third line) - Benefit assessment according to §35a Social Code Book V
Last updated 03.02.2025
Project no.:
A24-108
Commission:
Commission awarded on 01.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more prior systemic therapies
Result of dossier assessment:
- Patients who are eligible for CAR-T cell therapy or stem cell therapy: added benefit not proven
- Patients who are not eligible for CAR-T cell therapy and stem cell therapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-108
| Project no. | Title | Status |
|---|---|---|
| G23-27 | Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| A24-95 | Epcoritamab (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |